1.
|
Phase: Phase IV Type: Health services research, Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: Plerixafor-UF01, NCT01339572
|
|
2.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CCBX001-049, NCT00078598
|
|
3.
|
Phase: Phase III Type: Treatment Status: Active Age: 54 and under Sponsor: Other Protocol IDs: 0107M05202, MT2001-02, NCT00176930
|
|
4.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: Hx-CD20-405, GENMAB-Hx-CD20-405, OHSU-2634, NCT00394836
|
|
5.
|
Phase: Phase III Type: Treatment Status: Active Age: 16 to 65 Sponsor: NCI Protocol IDs: CBMTG-0601, NCT00438958
|
|
6.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GAO4753g, GO01297, NCT01059630
|
|
7.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 110918, NCT01077518
|
|
8.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: 113676, NCT01200589
|
|
9.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Supportive care, Treatment Status: Active Age: not specified Sponsor: NCI, Other Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
|
|
10.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 to 70 Sponsor: NCI, Other Protocol IDs: 715, 2U10HL069294-11, NCT01597778
|
|
11.
|
Phase: Phase III Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CR100840, PCI-32765CLL3001, 2012-000600-15, U1111-1135-3745, NCT01611090
|
|
12.
|
Phase: Phase III Type: Treatment Status: Active Age: 65 and over Sponsor: Pharmaceutical / Industry Protocol IDs: PCYC-1116-CA, 2012-003968-44, NCT01724346
|
|
13.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GS-US-313-0124, NCT01732913
|
|
14.
|
Phase: Phase III Type: Treatment Status: Active Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: GS-US-313-0125, NCT01732926
|
|
15.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Not specified Sponsor: NCI, Other Protocol IDs: 95-024, P30CA008748, MSKCC-95024, NCI-V95-0685, NCT00002663
|
|
16.
|
Phase: Phase II, Phase I Type: Supportive care, Treatment Status: Active Age: 18 and over Sponsor: NCI Protocol IDs: NCI-97-C-0110, NCT00019305
|
|
17.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 65 and under Sponsor: NCI, Other Protocol IDs: 1409.00, NCI-2010-00130, P01CA078902, FHCRC-1409.00, 4903, NCI-G00-1776, NCT00005803
|
|
18.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: 8713-HIMSUM, NCT00058825
|
|
19.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 to 75 Sponsor: NCI, Other Protocol IDs: CDR0000447204, P30CA016058, OHSU-HEM-05011-L, OHSU-210, NCT00245037
|
|
20.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: NCI, Other Protocol IDs: 05-103, MSKCC-05103, NCT00295932
|
|
21.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 69 Sponsor: NCI Protocol IDs: 070195, 07-C-0195, NCI-07-C-0195, NCT00520130
|
|
22.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 70 and under Sponsor: Other Protocol IDs: BCM-H-19386, BCM-FAB, H 19386, NCT00625144
|
|
23.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: 18 and over Sponsor: Other Protocol IDs: FDA IND 100712, NCT00611208
|
|
24.
|
Phase: Phase II, Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Active Age: 18 to 85 Sponsor: NCI, Other Protocol IDs: CDR0000615128, P30CA069533, OHSU-4180, HEM-08002-L, MERCK-OHSU-4180, 4180, OHSU-HEM-08002-L, NCT00764517
|
|
25.
|
Phase: Phase II, Phase I Type: Treatment Status: Active Age: Any age Sponsor: NCI, Other Protocol IDs: 2230.00, NCI-2010-00106, P01CA078902, FHCRC-2230.00, IR-6771, NCT00789776
|